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This study was designed in order to establish the perception of breathlessness during rest and while breathing
against resistance, in patients with asthma, before and after 8 weeks of inhaled glucocorticoids (IGC) treatment and
to compare these parameters in patients with and without improvement in FEV1.
Sixty-seven asthmatic patients, with moderate asthma, attending the asthma clinic, and 20 normal subjects were
studied. After a 2-week run-in period, in which the subjects were asked to use exclusively b2-agonists as needed, the
asthmatic patients were randomized to receive either treatment with IGC, 250 mg of fluticasone propionate (FP)
twice a day, via a diskhaler (47 patients), or to receive placebo (20 patients) and to serve as a control group, for 8
weeks. Spirometry and measurements for the sensation of dyspnoea were performed before and at the end of the
treatment period.
The mean dyspnoea score during breathing against resistance was significantly lower (P5005) in the patients
with asthma than in normal subjects, before entering the study. Following 8 weeks of inhaled FP, there was a
significant improvement in the mean dyspnoea score during breathing against resistance in the asthmatics receiving
IGCs but not in the control group (P5005). In the study group 32 patients had an improved FEV1415% and 15
patients did not. There was a statistically significant dierence in perception of dyspnoea (P5001), between the
group of patients with a improved FEV1 and the group of patients that were under IGC treatment without
improvement in their FEV1. There was also a dierence in the mean b2-agonists consumption between the two
groups (P5001).
Asthmatic patients have a significantly lower perception of dyspnoea compared to normal subjects. IGC
treatment was associated with increased perception of dyspnoea. However, this improvement was noted only in
patients with improved FEV1, while the patients without improvement remained with an equal degree of dyspnoea
perception and b2-agonists consumption.
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It is well documented that, in patients with asthma, there is
a considerable variation in the severity of breathlessness for
any particular degree of airflow obstruction (1). The factors
underlying this variability are still to be explored. Previous
studies have shown that among those factors which can
aect perception of dyspnoea related to bronchoconstric-
tion are changes in lung volumes, speed of bronchocon-
striction, anxiety level, duration of asthma and age (2–5).
Recently, it has been suggested by Roisman et al. (6) that
airway inflammation could also modulate perception of
bronchoconstriction. Negative correlation between theReceived 13 July 1999 and accepted in revised form 6 October
1999.
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and both the magnitude of eosinophilic inflammation in
airway mucosa and the degree of epithelial damage, were
noted by them. Moreover, patients receiving inhaled
glucocorticoids (IGCs) had a greater perception of bronch-
oconstriction than patients not using IGCs. However, the
authors did not relate the improved perception of breath-
lessness to the degree of the FEV1 and it can still be
speculated that this improvement corresponded to an
improvement in FEV1 rather than to the anti-inflammatory
eect of the drug. The information on how asthma
medications can modulate perception of respiratory symp-
toms is of the utmost importance, as most of the time
patients adjust their medication according to the respira-
tory symptoms and rescue medication needs.
The purpose of the present study was to establish the
perception of breathlessness during rest and while breathing
against resistance, to relate it to the degree of FEV1, before
and after 8 weeks of IGC treatment. We also hoped to# 2000 HARCOURT PUBLISHERS LTD
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under IGC treatment with no change in FEV1.
Methods
Sixty-seven asthmatic patients with moderate asthma,
attending the asthma clinic, and 20 normal subjects were
studied. All the asthmatic patients satisfied the American
Thoracic Society definition of asthma, with symptoms of
episodic wheezing, cough and shortness of breath, respond-
ing to bronchodilators, and reversible airflow obstruction
documented in at least one previous pulmonary function
study (7). All patients had moderate asthma (defined by
80%5FEV1560% of predicted normal values). All were
on rescue b2-agonists and no subject received inhaled or
oral corticosteroids for at least 3 months before inclusion.
All were in a stable state of their disease before and during
the study. Their characteristics are summarized in Table 1.
STUDY DESIGN
After inclusion, the subjects were asked to use exclusively
b2-agonists as needed for a bronchodilators alone run-in
period of 2 weeks. After the 2-week run-in period subjects
were randomized to receive either inhalation of glucocorti-
costeroids (IGC), 250 mg of fluticasone propionate (FP)
twice a day, via diskhaler per 8 weeks (47 patients-study
group), or to receive placebo (20 patients-control group).
The subjects used daily diary cards to record b2-agonists
consumption and inhaled FP usage.
TESTS
All tests were performed before and at the end of the
treatment period.
SPIROMETRY
Pulmonary functions were assessed by spirometry, per-
formed before and at the end of the treatment period. The
forced vital capacity (FVC) and the forced expiratoryTABLE 1. Characteristics of normal subjects and patients




Age (years) 39+36 36+28
Sex (M/F) 11/9 41/26
FEV1 (% of pred.) 101+62 74+46
FEV1/FVC (%) 83+20 77+39
Mean b2-agonist
consumption (per day) 31+04
*Mean+SEMvolume in 1 sec (FEV1) were measured three times on a
computerized spirometer (Compact, Vitalograph, Bucking-
ham, England) and the best trial is reported. Bronchodi-
lators were withheld 12 h before spirometry.
PERCEPTION OF DYSPNOEA
The sensation of dyspnoea was measured while the subject
breathed through a device similar to that proposed by
Nickerson and Keens (8). Subjects inspired through a two-
way Hans-Rudolph valve whose inspiratory port was
connected to a chamber and plunger to which weights
could be added externally. The subjects breathed against
progressive resistance, at 1-min intervals, in order to
achieve mouth pressure of 0 (no resistance), 5, 10, 20 and
30 cm H2O. After breathing for 1 min in each level of
resistance, in a protocol similar to the one that has been
previously described by Kikuchi et al. (9), using a method
recently published by Larsen et al. (10) with the same device
as ours, the subjects rated the sensation of diculty in
breathing (dyspnoea) using a modified Borg scale (10). This
is a linear scale of numbers ranking the magnitude of
diculty in breathing, ranging from 0 (none) to 10
(maximal).
DATA ANALYSIS
The results are expressed as meansSEM. Correlations were
assessed by calculating Spearman correlation coecients.
Comparisons of lung function and dyspnoea score were
carried out using the Anova two-way repeated measures
analysis of variance.
Results
At the entry to the study there was no significant dierence
in age or sex between the normal subjects and the study
group (Table 1). Mean FEV1, in the asthmatic patients was
74% of predicted normal values with mean daily b2-
agonists consumption of 3.1 pus day7l.
Following 8 weeks of inhaled FP or placebo treatment,
two groups of patients could be defined in the study group,
in addition to the control group; a group of 32 patients who
improved their FEV1 415% and a group of 15 patients
who did not. The characteristics of the dierent groups are
summarized in Table 2. The three groups did not dier
significantly in age, sex and FEV1, before the study.
Following the treatment period there was no dierence in
mean FEV1 and the b2-agonists consumption between the
‘without improved FEV1 group’ and the control group.
However, the dierences in the mean FEV1 and the b2-
agonists consumption between the ‘improved FEV1 group’
and the two other groups were statistically significant
(P5005 and P5001 respectively). According to their
diaries, compliance for inhaled steroids or placebo were
similar in the three groups.
The mean Borg score during breathing against resistance
was significantly lower (P5001) in the patients with
TABLE 2. Characteristics of patients with asthma, after 8
weeks of treatment with EP/Placebo*
Study group
With Without
Improved FEV1 Control group
Characteristic
No 32 15 20
Sex (M/F) 18/14 11/4 12/8
Age (years) 37+39 34+26 35+31
FEV1 (% of pred.) 89+53 79+30 75+32
FEV1/FVC (%) 81+23 78+39 74+37
Mean b2-agonist
consumption (per day) 14+02 30+06 34+06
compliance 087+01 088+01 085+02
*Mean+SEM
FIG. 1. Mean+SEM perception of dyspnoea (Borg score)
during breathing against resistance in the patients with
asthma and in normal subjects (before entering the study),
and in the asthmatics following the treatment period. –*
–: Normal; –* –: asthma-before; –& –: asthma-after; –~
– asthma control-after.
FIG. 2. Mean+SEM perception of dyspnoea (Borg score)
during breathing against resistance in the patients with
asthma before entering the study and in the two
subgroups of the study group, following the treatment
period. –* –: asthma-before; –& –: asthma improved-
after; –& –: asthma not improved-after.
FIG. 3. Perception of dyspnoea (Borg score) during
breathing against resistance that creates a negative
pressure of 20 cm H2O, in the patients with asthma and in
normal subjects (before entering the study), and in the
asthmatics following the treatment period.
DYSPNOEA AND INHALED GLUCOCORTICOSTEROID TREATMENT 163asthma than in normal subjects, before entering the study
(Fig. 1). Following the treatment period, there was a
statistically significant increase in perception of dyspnoea
(P5005), in the study group but not in the control group.
However, looking at the two subgroups of the study group
it is prominent that only in the patients of the ‘improved
FEV1 group’ there was a statistically significant increase in
perception of dyspnoea (P5001), compared to baseline
values (Fig. 2). There was no change in perception ofdyspnoea, in the group of patients that were under IGC
treatment without improvement in their FEV1 .
The Borg scores of individual patients during breathing
with resistance to create mouth pressure of 20 cm of water
are shown in Fig. 3. The mean score for the patients with
asthma, before IGC treatment, was significantly lower than
that for the normal subjects (2.6+02 vs 3.7+03, P5001).
FIG. 4. Perception of dyspnoea (Borg score) during
breathing against resistance that creates a negative
pressure of 20 cm H2O, in the patients with asthma before
entering the study, in the control group and in the two
sub-groups of the study group, following the treatment
period.
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treatment with IGC but not in the asthmatics receiving
placebo (Fig. 3). It is clear again that the improvement in
perception of dyspnoea, is mainly due to the improvement
observed in the subgroup of patients that were under IGC
treatment with improvement in their FEV1 (Fig. 4).
Discussion
In this study, we have shown that asthmatic patients, with
moderate airflow obstruction, have a significantly lower
perception of dyspnoea compared to normal subjects. IGC
treatment was associated with increased perception of
dyspnoea. However, this increase was noted only in patients
that improved their FEV1, while the patients without
improvement remained with equal degree of dyspnoea
perception and b2-agonists consumption, suggesting that
IGC-induced improvement in perception of dyspnoea is
mainly associated with improvement in airflow.
In the management of bronchial asthma the subject’s
perception of dyspnoea serves as one of the most important
indexes used to guide treatment. It is well documented that
large variations in perception of respiratory symptoms may
be observed from one asthmatic subject to another (12).
Kendrick et al. have already shown that in 60% of
asthmatics there is no correlation between the POD and
simultaneous peak flow measurements (13). Low perception
of dyspnoea may result in undertreatment of asthma, delaymodification in treatment (14) and even may predispose
patients to fatal asthma attacks (9).
Among the dierent factors that may influence percep-
tion of asthma symptoms, airway inflammation and anti-
inflammatory medications have been proposed. In this
regard, Roisman et al. (6) suggested that, in asthmatic
patients, perception of bronchoconstriction is related to
eosinophylic inflammation and to epithelial damage in
airways. In addition, they have suggested that corticoster-
oid treatment is associated with improved perception of
bronchoconstriction induced by bradykinin, a mediator
endogenously produced in asthma. They hypothesized that
IGC, by reducing the airway inflammation, improve the
perception of bronchoconstriction. This hypothesis con-
flicts with our observation that the improvement in the
perception of bronchoconstriction was noted only in
patients that improved their FEV1, while the patients
without improvement remained with equal degree of
dyspnoea perception and b2-agonists consumption, follow-
ing IGC treatment. In the present study we made no
measurements of airway inflammation and thus we cannot
tell if the dierence in perception between the subjects with
improved airflow and the patients without improvement are
due to lesser degree of airway inflammation. However, it
was already shown that even in the pre-asthmatic state and
in mild asthma, with normal or near-normal FEV1 (15,6),
significant airway inflammation and epithelial damage
occur, and IGC use may restore the integrity of the
epithelium (17), with no change in airflows. Therefore, it
can be assumed that in our group of patients, without
improvement in their FEV1, despite IGC’s anti-inflamma-
tory eect, no improvement of perception of bronchocon-
striction occurred.
Assessment of perception of breathlessness has been
performed using dierent techniques. It was measured
following antigen, exercise, histamine, or methacholine-
induced-bronchoconstriction (1,18,19) or during externally
added loading (9–11,20).
We preferred to use the method of adding external loads,
using the same method that was used by Larsen et al. This
method of breathing against incremental loads was found
to be reliable and reproducible. Kikuchi et al. (9) described
a similar method using added resistance instead of added
threshold loads. Previous studies have shown that some
factors that are related to the method of inducing
bronchoconstriction, such as hyperinflation of the lung
and its unfavourable consequences on respiratory muscle
function (21,22), the speed of bronchoconstriction (2–5),
and other eects of the various agents that are used which
may have other eects on the airway system beside just
increasing the RAW (23), can aect perception of dyspnoea
related to bronchoconstriction.
Breathlessness associated with bronchoconstriction in
asthmatic subjects originates in complex and not yet fully
understood mechanism. Increase in the resistive work of
breathing is playing some role in causing breathlessness
(24,25) through activation of respiratory muscles. Hyperin-
flation of the lung and higher intrathoracic pressure,
resulting from an increased airway resistance may also
contribute to respiratory discomfort (26). In addition,
DYSPNOEA AND INHALED GLUCOCORTICOSTEROID TREATMENT 165non-mechanical stimuli such as airway C fibers activated by
inflammatory mediators may contribute to the perception
of dyspnoea (26,27) and it was shown that airway
inflammation and the integrity of the airway epithelium
influence the perception of induced bronchoconstriction
(6). However, according to the result of our study, it is
dicult to establish the role of inflammation and how IGC
can modulate perception of respiratory symptoms, in
patients with asthma.
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